Table 1.

Examples of ADCs and TPDs with key features and FDA Approval Status for NSCLC.

Treatment Strategy	Target	Drug/Compound	Key Features	Fda Approval Status	Reference
ADC	HER2	Trastuzumab emtansine	Has shown efficacy in HER2-positive breast cancer	Not approved for NSCLC	[91]
ADC	HER2	Trastuzumab deruxtecan	ORR 55%, median PFS 8.2 months in HER2-mutant NSCLC	Approved for HER2- mutant metastatic NSCLC (2022)	[97]
ADC	HER3	Patritumab deruxtecan	ORR 39%, median PFS 8.2 months in EGFR-TKI-resistant patients	Not approved	[92]
ADC	MET	Telisotuzumab vedotin	Under evaluation with osimertinib and docetaxel	Not approved	[98]
ADC	TROP2	Sacituzumab govitecan	Has shown good clinical activity in most solid tumor types	Not approved for NSCLC	[85]
TPD	EGFRDel19, EGFRL858R/T790M	PROTAC EGFR degraders	Cellular and preclinical antitumor activity	Not approved	[99]
	KRASG12C	PROTAC KRAS degraders		Not approved
	ALK	PROTAC ALK degraders		Not approved
	BRAFV600E	PROTAC BRAF degraders		Not approved
	BCL-XL	PROTAC BCL-XL degraders		Not approved